一种新型预后模型对慢性粒单核细胞白血病患者异基因造血干细胞移植结局的影响
该研究通过衍生队列的多因素Cox回归识别移植后生存独立危险因素,构建ABLAG预后模型(年龄、骨髓原始细胞、白细胞、贫血、慢性移植物抗宿主病),将患者分为低、中、高危三组,3年总生存率分别为93.3%、78.9%和51.6%(p < .001),内部与外部验证的ROC曲线下面积分别为0.829和0.749。
要点
- 多因素分析显示高龄(HR 3.583)、白细胞计数(HR 3.499)、贫血(HR 3.439)、骨髓原始细胞计数(HR 2.095)及无慢性移植物抗宿主病(HR 4.799)与更差生存独立相关。
- ABLAG模型将患者分为低危(0-1分)、中危(2-3分)和高危(4-6分),3年总生存率分别为93.3%(95%CI 61%-99%)、78.9%(95%CI 60%-90%)和51.6%(95%CI 32%-68%)(p < .001)。
- 内部验证和外部验证的ROC曲线下面积分别为0.829(95%CI 0.776-0.902)和0.749(95%CI 0.684-0.854)。
核心结论
- 结合疾病特征与患者特征,ABLAG模型为接受异基因造血干细胞移植的CMML患者提供了更好的生存分层。
研究设计与样本
- 通过衍生队列应用单因素和多因素Cox比例风险回归识别风险因素,开发ABLAG预后模型,并在内部和外部验证队列中评估。
主要发现
- 多因素分析中,高龄(HR 3.583)、白细胞计数(HR 3.499)、贫血(HR 3.439)、骨髓原始细胞计数(HR 2.095)及无慢性移植物抗宿主病(HR 4.799)与更差生存独立相关。
- 低危(0-1分)、中危(2-3分)和高危(4-6分)三组的3年总生存率分别为93.3%(95%CI 61%-99%)、78.9%(95%CI 60%-90%)和51.6%(95%CI 32%-68%)(p < .001)。
- 内部验证和外部验证的ROC曲线下面积分别为0.829(95%CI 0.776-0.902)和0.749(95%CI 0.684-0.854)。
- 校准曲线和决策曲线分析显示ABLAG模型预测结局与实际观察结局高度一致,患者可从该模型获益。
关键数值与推荐
- ABLAG模型评分:低危0-1分,中危2-3分,高危4-6分。
- 低危、中危、高危三组3年总生存率分别为93.3%(95%CI 61%-99%)、78.9%(95%CI 60%-90%)和51.6%(95%CI 32%-68%)(p < .001)。
- 内部验证ROC曲线下面积0.829(95%CI 0.776-0.902),外部验证ROC曲线下面积0.749(95%CI 0.684-0.854)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Chronic myelomonocytic leukemia (CMML) is a clonal hematopoietic stem cell malignancy, and allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the only curable treatment. The outcomes after transplant are influenced by both disease characteristics and patient comorbidities. To develop a novel prognostic model to predict the post-transplant survival of CMML patients, we identified risk factors by applying univariable and multivariable Cox proportional hazards regression to a derivation cohort. In multivariable analysis, advanced age (hazard ratio [HR] 3.583), leukocyte count (HR 3.499), anemia (HR 3.439), bone marrow blast cell count (HR 2.095), and no chronic graft versus host disease (cGVHD; HR 4.799) were independently associated with worse survival. A novel prognostic model termed ABLAG (Age, Blast, Leukocyte, Anemia, cGVHD) was developed and the points were assigned according to the regression equation. The patients were categorized into low risk (0-1), intermediate risk (2, 3), and high risk (4-6) three groups and the 3-year overall survival (OS) were 93.3% (95%CI, 61%-99%), 78.9% (95%CI, 60%-90%), and 51.6% (95%CI, 32%-68%; p < .001), respectively. In internal and external validation cohort, the area under the receiver operating characteristic (ROC) curves of the ABLAG model were 0.829 (95% CI, 0.776-0.902) and 0.749 (95% CI, 0.684-0.854). Compared with existing models designed for the nontransplant setting, calibration plots, and decision curve analysis showed that the ABLAG model revealed a high consistency between predicted and observed outcomes and patients could benefit from this model. In conclusion, combining disease and patient characteristic, the ABLAG model provides better survival stratification for CMML patients receiving allo-HSCT.
引用
- Zhou JY, Wang S, Yuan HL, et al. Impact of a novel prognostic model on allogeneic hematopoietic stem cell transplantation outcomes in patients with CMML. Am J Hematol. 2023. PMID: 37366294. doi:10.1002/ajh.26999
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。